NCT07388979尚未招募不适用
MAGIa In-vitro- Diagnostics Medical Device Dedicated to Combined Screening of HIV, HBV, HCV and Syphilis and HBV Reflective Panels aMong Congolese pregnAnt woMen Attending to Ante Natal Care Consultations
Gardiens de Vies0 个研究点目标入组 7,500 人开始时间: 2026年3月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 7,500
- 主要终点
- Performance evaluation of MagIA H3S in detection of HIV-Ab, HBAg, HCV-Ab and TP-Ab
研究概览
简要总结
Performance study to evaluate the clinical performance of the In-Vitro Diagnostic Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from pregnant women attending antenatal care (ANC) services in the Democratic Republic of the Congo. This study aligns with the WHO 2022-2030 strategy for the integrated elimination of mother-to-child transmission of HIV, HBV, HCV, and syphilis.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Being pregnant, regardless of age or stage of pregnancy (prenatal period);
- •Having signed an informed consent form at the start of prenatal care (CPN) to participate in the study.
- •Note: for pregnant minors, the consent of a parent or legal guardian is required;
- •Have chosen to attend prenatal care at the healthcare facility selected for the study;
- •Plan to give birth at the same healthcare facility where they were included in the study;
- •Plan to attend postnatal care (PNC) and preschool consultations (PSC) at the same healthcare facility where they were included in the study.
- •Plan to give birth at the same health facility where they were enrolled;
- •Plan to attend postnatal consultations (PNC) and preschool consultations (PSC) at the same facility
排除标准
- •Women in labor or who refuse to give their consent.
结局指标
主要结局
Performance evaluation of MagIA H3S in detection of HIV-Ab, HBAg, HCV-Ab and TP-Ab
时间窗: Baseline
Compare the sensitivity and specificity of the MAGIA H3S test with laboratory reference tests (ELISA/EIA for HIV, HBV and HCV, and syphilis) for detecting the following four markers in Congolese pregnant women: anti-HIV antibodies, anti-HCV antibodies, HBsAg and treponemal antibodies for syphilis.
次要结局
- Positive predictive value (PPV) and negative predictive value (NPV) of MagiA H3S device(Baseline)
- Sensitivity and specificity of MagiA H3S device to dignose HIV, HBV, HCV and syphilis.(Baseline)
- Stratum-specific sensitivity and specificity of the H3S test.(Baseline)
- SE and SP, PPV and NPV of the MagIA TREATB test among pregnants women.(Up to 4 weeks)
- Se and Sp of the MagIA TREAT-B test in postpartum women, 6 months after delivery(6 month post partum)
- Number and types of usage errors observed during the study as well as any malfunctions of the MagiA H3S device.(Baseline)
- Cotation of usability of the MagiA device from the users' perspective.(From baseline)
- Prevalence of HIV, hepatitis B and C viruses, and syphilis among pregnant women in the DRC.(Up to 4 weeks from baseline)
- Proportion of pregnant women who accepted the antenatal screening of HIV, HBV, HCV and Syphilis(Baseline)
- Proportion of positive results returned to pregnant women attending prenatal clinics in selected sites in the DRC.(Baseline)
- Cotation of Treatment adherence among positive pregnant women recieving treatment(Through study completion, an average of 2 year)
- Proportion of vaccinated newborn born from positive HBV positive pregnants women within the first 24 hours.(At delivery)
- Rate of mother-to-child transmission for HIV, syphilis, HCV, and HBV.(Four to six weeks after birth for HIV, Six months after birth for HBV, at birth for syphilis and six weeks to tree months after birth for HCV post partum)
- Cost-effectiveness of the MAGIA H3S diagnostic test(Perioperative/Periprocedural)
- Cost-effectiveness of the MAGIA TREAT B diagnostic test to identify pregnant women eligible for antiviral prophylaxis against hepatitis B(Perioperative/Periprocedural)
- Cost-effectiveness of the MAGIA TREAT B diagnostic test to identify women infected with hepatitis B virus who are eligible for long-term treatment for their own health(through study completion, an average of 2 years.)
- Odds of pregnant women's preference regarding HBV diagnostic strategy for antenatal prophylaxis.(One month after inclusion)
- Cotation of the capacity of health facilities to provide essential hepatitis care services(1 to 2 months before the begining of the study)
研究者
MAINDO ALONGO
Principal Investigator
Gardiens de Vies
相似试验
招募中
不适用
Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)SyphilisNCT07170748MagIA Diagnostics2,950
招募中
不适用
In Vivo Evaluation of the Accuracy of Immediate Screw-Retained Provisional Crowns Fabricated Using Digital Planning and Guided SurgeryNCT07315607Universidad Complutense de Madrid27
招募中
不适用
Local Treatment of Breast Pain Based on the Daily Use of a Topical GelNCT07257770Lo.Li.Pharma s.r.l50
Enrolling By Invitation
1 期
Handheld MPI Imaging to Track Stem Cells in OsteoarthritisNCT07313020Soochow University10
已完成
不适用
Diagnostic Accuracy of Carebot AI MMG in Mammography Screening: Multicenter MRMC StudyNCT07298252Carebot s.r.o.222